{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:48:48Z","timestamp":1789145328538,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.neuropharm.2018.08.022","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T17:44:48Z","timestamp":1535046288000},"page":"214-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice"],"prefix":"10.1016","volume":"141","author":[{"given":"Karolina","family":"Podkowa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Podkowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Pa\u0142ucha-Poniewiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.08.022_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib2","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1523\/JNEUROSCI.1497-06.2006","article-title":"Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice","volume":"26","author":"Callaerts-Vegh","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuropharm.2012.05.022","article-title":"MGlu2\/3 and mGlu5 receptors: potential targets for novel antidepressants","volume":"66","author":"Chaki","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mp.2016.34","article-title":"Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects","volume":"22","author":"Chowdhury","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib5","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1046\/j.1460-9568.1998.00371.x","article-title":"Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8","volume":"10","author":"Corti","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci","volume":"29","author":"Cryan","year":"2005","journal-title":"BioBehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib7","first-page":"81","article-title":"Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem","volume":"95","author":"Dale","year":"2015","journal-title":"Pharmacology (Basel)"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2174\/1570159X13666150630173522","article-title":"Challenging treatment-resistant major depressive disorder: a roadmap for improved therapeutics","volume":"13","author":"de Sousa","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.biopsych.2012.09.031","article-title":"Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review","volume":"73","author":"Drevets","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jps.3030460322","article-title":"A note on a simple apparatus for detecting neurological deficit in rats and mice","volume":"46","author":"Dunham","year":"1957","journal-title":"J. Am. Pharm. Assoc. JAPhA"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial","volume":"63","author":"Furey","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00004714-198504000-00003","article-title":"Ketamine: behavioral effects of subanesthetic doses","volume":"5","author":"Ghoneim","year":"1985","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1101\/lm.98305","article-title":"Lack of the metabotropic glutamate receptor subtype 7 selectively modulates Theta rhythm and working memory","volume":"12","author":"H\u00f6lscher","year":"2005","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040622315579059","article-title":"Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review","volume":"6","author":"Iadarola","year":"2015","journal-title":"Ther. Adv. Chronic Dis"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40473-016-0075-4","article-title":"Current trends in identifying rapidly acting treatments for depression","volume":"3","author":"Ionescu","year":"2016","journal-title":"Cur. Behav. Neurosci. Rep"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/WNF.0b013e318278b703","article-title":"Scopolamine as an antidepressant: a systematic review","volume":"36","author":"Jaffe","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(72)93021-8","article-title":"A cholinergic-adrenergic hypothesis of mania and depression","volume":"300","author":"Janowsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","article-title":"The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies","volume":"34","author":"Klinkenberg","year":"2010","journal-title":"Neurosci. BioBehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0929-6646(11)60031-4","article-title":"Delirium due to scopolamine patch in a 4-year-old boy","volume":"110","author":"Lin","year":"2011","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vascn.2017.04.006","article-title":"Comparison of pro-amnesic efficacy of scopolamine, biperiden, and phencyclidine by using passive avoidance task in CD-1 mice","volume":"86","author":"Malikowska","year":"2017","journal-title":"J. Pharmacol. Toxicol. Meth."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib23","first-page":"492","article-title":"Further evaluation of mechanisms associated with the antidepressant-like signature of scopolamine in mice. CNS Neurol. Disord","volume":"16","author":"Martin","year":"2017","journal-title":"Drug Targets"},{"issue":"1771\u20133","key":"10.1016\/j.neuropharm.2018.08.022_bib24","first-page":"1776","article-title":"The management of depression. Part 2. The place of the new antidepressants","volume":"23","author":"Mitchell","year":"1994","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib25","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1073\/pnas.0508063102","article-title":"A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo","volume":"102","author":"Mitsukawa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/sj.npp.1300926","article-title":"Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders","volume":"31","author":"Mitsukawa","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.biopsych.2013.08.011","article-title":"Scopolamine and ketamine: evidence of convergence?","volume":"74","author":"Monteggia","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2015.06.012","article-title":"Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors","volume":"82","author":"Navarria","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FBP.0b013e32835efc78","article-title":"The effects of mGlu\u2087 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains","volume":"24","author":"O'Connor","year":"2013","journal-title":"Behav. Pharmacology (Basel)"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2010.02.059","article-title":"Metabotropic glutamate receptor 7: at the interface of cognition and emotion","volume":"639","author":"O'Connor","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbr.2008.10.029","article-title":"Evaluation of spatial memory of C57BL\/6J and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze","volume":"198","author":"Patil","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2007.04.007","article-title":"Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs","volume":"115","author":"Pa\u0142ucha","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00213-007-0856-2","article-title":"Activation of the mGlu7 receptor elicits antidepressant-like effects in mice","volume":"194","author":"Pa\u0142ucha","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17460441.2016.1213234","article-title":"Glutamate-based drug discovery for novel antidepressants","volume":"11","author":"Pa\u0142ucha-Poniewiera","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/jpet.110.169730","article-title":"The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N\u2019-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent","volume":"334","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2014.03.001","article-title":"Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats","volume":"82","author":"Pa\u0142ucha-Poniewiera","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuropharm.2016.08.031","article-title":"Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495","volume":"111","author":"Podkowa","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib38","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s00213-016-4325-7","article-title":"Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats","volume":"233","author":"Podkowa","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pharep.2015.08.007","article-title":"The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect","volume":"68","author":"Pytka","year":"2016","journal-title":"Pharmacol. For. Rep."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.ftd.0000168293.48226.57","article-title":"Pharmacokinetics and pharmacodynamics in clinical use of scopolamine","volume":"27","author":"Renner","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/jnnp.13.1.47","article-title":"The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis","volume":"13","author":"Rowntree","year":"1950","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib43","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1523\/JNEUROSCI.21-22-08734.2001","article-title":"Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7","volume":"21","author":"Sansig","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00210-013-0847-2","article-title":"Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice","volume":"386","author":"Sa\u0142at","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0006-3223(03)00420-7","article-title":"Social and economic burden of mood disorders","volume":"54","author":"Simon","year":"2003","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(99)00330-1","article-title":"Antidepressants for the new millennium","volume":"375","author":"Skolnick","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.08.022_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.110.177378","article-title":"The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?","volume":"338","author":"Sukoff Rizzo","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","article-title":"Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses","volume":"74","author":"Voleti","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.08.022_bib52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an NMDA antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:17:20Z","timestamp":1617621440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818305495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":51,"alternative-id":["S0028390818305495"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.022","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}